After decades of stagnation in the schizophrenia field, Bristol Myers Squibb’s $14 billion deal for Karuna Therapeutics has ...

Bristol Myers Squibb's Cobenfy has been approved by the FDA as the first new treatment for schizophrenia in decades. The ...

The FDA has approved the first treatment for schizophrenia that targets cholinergic receptors rather than dopamine receptors.

What comes next for Pfizer's Oxbryta sickle cell drug —Cassava Sciences' SEC charges —Bristol's new schizophrenia treatment ...

The FDA has approved Cobenfy, a dual M1/M4 muscarinic agonist that offers a fundamentally different approach to treating ...

The drug was developed by Karuna Therapeutics, which was bought by Bristol Myers Squibb (BMS) last year for $14 billion. This is the first new class of treatment for the psychiatric disorder since ...

Based largely on Cobenfy’s promise, Bristol Myers Squibb paid $14 billion to acquire the company that developed the drug, ...

A medicine that sidesteps the brain's dopamine receptors to reach different targets represents a new approach to ...

Bristol Myers Squibb's drug, KarXT, improved symptoms of adults with schizophrenia and had fewer side effects than antipsychotic treatments ...

This approval triggers 2 milestone payments totaling $29 million, as per agreements with Royalty Pharma and PureTech's founded entity, Karuna Therapeutics, which was acquired by Bristol Myers Squibb ...

Bristol Myers Squibb BMY announced that the FDA has approved xanomeline and trospium chloride (formerly KarXT), an oral ...

The U.S. Food and Drug Administration approved Bristol Myers Squibb's schizophrenia drug late on Thursday, making it the ...